Clinical trialNCT01831037WithdrawnObservational

The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study

SponsorUniversity of ArkansasEnrollment0Chronic Hepatitis BChronic Hepatitis C

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study aims to demonstrate that patients with chronic hepatitis C (CHC) and B (CHB) experiencing regression of liver cirrhosis after effective antiviral therapy have decreased risk for hepatocellular carcinoma (HCC). Primary aim is to determine the incidence of HCC in patients with cirrhosis secondary to CHC and CHB, after treatment is provided, and to identify the magnitude of the decreased risk for HCC in patients experiencing regression of fibrosis. As a secondary aim, environmental risk factors for HCC development will be sought, in order to determine a subset of patients in whom it will be safe to stop surveillance.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Andres Duarte-Rojo, MD, MSc
University of Arkansas
Principal Investigator
clinicaltrials.gov ↗
Jonathan A Dranoff, MD
University of Arkansas
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

University of Calgary
Calgary, Alberta, Canada
University of Toronto
Toronto, Ontario, Canada

United States

University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Jul 2015
Primary completion: 30 Jun 2019
Completion: 31 Dec 2019
Last update posted: 28 Jan 2015
Registered enrollment: 0
Registry id: NCT01831037

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.